ROCHESTER, NY, and LEXINGTON, MA – (Business Wire) MC10, Inc., creators of the innovative wearable device BioStamp nPoint, and the University of Rochester announced today a collaboration on advancing methods of assessing Central Nervous System (CNS) diseases. The collaboration will utilize the BioStamp nPoint system to collect continuous data allowing for the creation of algorithms to provide quantitative assessment of disease progression, specifically for movement disorders.
“Movement disorders such as Huntington’s and Parkinson’s disease represent a therapeutic area that lacks objective, quantitative understanding of disease progression, and therapeutic efficacy. The goals of this research collaboration are to enhance the way we assess people with CNS diseases, improve the way therapies are evaluated, and transform the way these patients are managed toward better outcomes,” said Dr. Arthur Combs, MD, Chief Medical Officer of MC10.
MC10 and the University of Rochester have a strong history of collaborations focused mainly on Central Nervous System developments, including prior studies on Parkinson’s and Huntington’s Disease patients. The upcoming research features more advanced technology and a larger sample size of participants to get a more complete and accurate data set, allowing for more robust algorithms and the creation of new digital biomarkers. MC10 hopes that these new algorithms and the insights gained during the research will be beneficial to many of BioStamp nPoint’s early adopters and improve understanding of movement disorder progression.
“Neurological disorders are the world’s leading source of disability. Unfortunately, drug development for these disorders is littered with failures in part because of shortcomings in traditional rating scales. We need more objective, continuous, sensitive, real-world assessments of how these disorders affect individuals than we can get from subjective rating scales. Wearable sensors, like those from MC10, have the potential to provide us such data. Data that we can use to determine whether new therapies are efficacious,” said Dr. Ray Dorsey, a professor of neurology and director of the Center for Health +Technology at University of Rochester.
The University of Rochester was recently named a Morris K. Udall Center of Excellence for Parkinson’s research and awarded a grant to work towards understanding the disease progression of the debilitating disease. Both companies hope that the efforts on this collaboration will serve as a basis for Parkinson’s research for years to come.
About University of Rochester
The University of Rochester (www.rochester.edu) is one of the nation’s leading private universities. Located in Rochester, N.Y., the University gives students exceptional opportunities for interdisciplinary study and close collaboration with faculty through its unique cluster-based curriculum. Its College, School of Arts and Sciences, and Hajim School of Engineering and Applied Sciences are complemented by its Eastman School of Music, Simon School of Business, Warner School of Education, Laboratory for Laser Energetics, School of Medicine and Dentistry, School of Nursing, Eastman Institute for Oral Health, and the Memorial Art Gallery.
MC10 is a privately held company focused on improving human health through digital solutions. The company combines conformal BioStamp sensors with clinical analytics to unlock novel insights from physiological data collected from the home or in clinical settings. Our flagship product, BioStamp nPoint, is marketed into the clinical research community. MC10 is headquartered in Lexington, MA. Visit MC10 online at https://www.mc10inc.com.
MC10®, BioStamp nPoint®, and the MC10 logo are registered marks owned by MC10, Inc.